Boehringer Ingelheim

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Results from the EMPEROR-Preserved phase 3 trial have demonstrated that empagliflozin, which is sold as Jardiance by Boehringer Ingelheim and Eli Lilly, showed a “significant” 21% relative risk reduction in

CureVac to push ahead with first- and second-generation COVID-19 vaccines

CureVac also announced that Boehringer Ingelheim had terminated a collaboration with the company to investigate treatments for lung cancer.

EFPIA confirms first and second vice-presidents

The EFPIA also confirmed Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim, as president for the next two years.

EFPIA appoints Hubertus von Baumbach as president

Von Baumbach currently serves as chairman of the board of managing directors at Boehringer Ingelheim, a role he was appointed to in 2016. ... Baumbach had been a member of Boehringer’s board of managing directors since 2009, and he has also previously

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

Together, in a move of collaboration I have never seen in my career, over 20 leading pharmaceutical companies formed the AMR Action Fund, which has since been joined by the Boehringer ... Ingelheim Foundation, the European Investment Bank and the

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]